Sherry Liu
| Sherry Liu | |
| Occupation | Entrepreneur, software engineer |
|---|---|
| Known for | Co-founder and CTO of Tamarind Bio |
| Education | Stanford University (B.S., Computer Science) |
Sherry Liu is an American entrepreneur and software engineer who is the co-founder and Chief Technology Officer (CTO) of Tamarind Bio, an artificial intelligence inference platform for drug discovery. The company, which participated in Y Combinator's Winter 2024 batch, provides researchers with access to computational biology tools without requiring coding expertise or high-performance computing infrastructure.[1]
Career
Liu studied computer science at Stanford University, where she conducted research in computational biology and machine learning applied to biological systems. During her studies, she met her eventual co-founder, Deniz Kavi. Prior to founding Tamarind Bio, Liu worked as a software engineer intern at Amazon Web Services (AWS), where she gained experience in scalable cloud computing infrastructure. She also conducted bioinformatics research at North Carolina State University and led machine learning research at Stanford focused on biology applications.[2]
In 2023, Liu and Kavi co-founded Tamarind Bio to address inefficiencies they observed in how scientists accessed and used computational biology tools. The company built a platform — available as both a website and an API — that allows scientists to run machine learning models such as AlphaFold for molecular design and simulation through a simple interface, eliminating the need to set up high-performance computing environments or manage DevOps processes.
The platform gained 600 users in its first month of operation and grew to serve thousands of researchers at large pharmaceutical companies, biotechnology firms, and academic institutions including Stanford, Harvard, and Oxford. Tamarind Bio expanded its offerings to over 200 models covering antibodies, peptides, small molecules, enzymes, and radiopharmaceuticals.
Liu's cloud computing experience from AWS informed the development of Tamarind's infrastructure, which handles hosting, compute provisioning, runtime orchestration, security, and data residency. The platform leverages AWS to scale from zero to 10,000 GPUs in minutes.
In 2025, Tamarind Bio raised a $13.6 million Series A round led by Dimension Capital, following initial seed funding from Y Combinator.[3]
References
- ↑ "Tamarind Bio – Y Combinator". 'Y Combinator}'. Retrieved 2026-03-18.
- ↑ "Tamarind Bio". 'Tamarind Bio}'. Retrieved 2026-03-18.
- ↑ "Tamarind Bio – Y Combinator". 'Y Combinator}'. Retrieved 2026-03-18.